KRAS and neoplasm: However, ESRP1 is significantly downregulated in PDAC, losing its tumor suppressor function.350 Besides, more than 90% of PDACs have KRAS mutations, primarily manifested as KRASG12D mutations, causing persistent activation of KRAS-related pathways.351 Pancreatitis will accelerate the progression of KRAS mutant PDAC.352 Wan et al.353 found that SRSF1 downregulation is a negative feedback response of cells to KRASG12D mutation.